WO1990001321A3 - Procede de traitement et de prevention de la perte de masse osseuse - Google Patents

Procede de traitement et de prevention de la perte de masse osseuse Download PDF

Info

Publication number
WO1990001321A3
WO1990001321A3 PCT/US1989/003341 US8903341W WO9001321A3 WO 1990001321 A3 WO1990001321 A3 WO 1990001321A3 US 8903341 W US8903341 W US 8903341W WO 9001321 A3 WO9001321 A3 WO 9001321A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
bone mass
active
treating
preventing loss
Prior art date
Application number
PCT/US1989/003341
Other languages
English (en)
Other versions
WO1990001321A2 (fr
Inventor
Hector F Deluca
Charles W Bishop
Richard B Mazess
John C Gallagher
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Priority to EP89910341A priority Critical patent/EP0381750B1/fr
Priority to DE68919673T priority patent/DE68919673T2/de
Priority to DE19893990902 priority patent/DE3990902T1/de
Publication of WO1990001321A2 publication Critical patent/WO1990001321A2/fr
Priority to GB9006990A priority patent/GB2231794B/en
Publication of WO1990001321A3 publication Critical patent/WO1990001321A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Processing Of Solid Wastes (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Disintegrating Or Milling (AREA)
  • Fertilizers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention décrit et revendique l'utilisation de 1α-vitamine D2 comme médicament dans le traitement de l'ostéoporose. Des composés actifs de vitamine D3 sont inefficaces ou ont une efficacité minime à des niveaux posologiques pouvant être tolérés par l'homme. A des niveaux posologiques requis afin de reconstituer efficacement la masse osseuse perdue, des composés actifs de vitamine D3 présentent une quantité de toxicité sérieuse sous forme d'hypercalcémie et hypercalciurie. Les inventeurs ont découvert que la 1α-vitamine D2 qui est aussi active que la 1α-vitamine D3 pour stimuler l'absorption intestinale de calcium, peut être administrée sans danger à des posologies supérieures à 3,0 νg/jour sans stimulation de la réabsorption osseuse.
PCT/US1989/003341 1988-08-02 1989-08-02 Procede de traitement et de prevention de la perte de masse osseuse WO1990001321A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP89910341A EP0381750B1 (fr) 1988-08-02 1989-08-02 Procede de traitement et de prevention de la perte de masse osseuse
DE68919673T DE68919673T2 (de) 1988-08-02 1989-08-02 Verfahren zur behandlung und vorbeugung des verlustes von knochenmasse.
DE19893990902 DE3990902T1 (de) 1988-08-02 1989-08-02 Verfahren fuer die behandlung und vermeidung eines abbaus von knochensubstanz
GB9006990A GB2231794B (en) 1988-08-02 1990-03-28 Method for treating and preventing loss of bone mass

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22737188A 1988-08-02 1988-08-02
US227,371 1988-08-02

Publications (2)

Publication Number Publication Date
WO1990001321A2 WO1990001321A2 (fr) 1990-02-22
WO1990001321A3 true WO1990001321A3 (fr) 1990-05-17

Family

ID=22852835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/003341 WO1990001321A2 (fr) 1988-08-02 1989-08-02 Procede de traitement et de prevention de la perte de masse osseuse

Country Status (11)

Country Link
EP (1) EP0381750B1 (fr)
JP (1) JP3030854B2 (fr)
AT (1) ATE114471T1 (fr)
AU (1) AU634490B2 (fr)
CA (1) CA1341408C (fr)
DE (1) DE68919673T2 (fr)
GB (1) GB2231794B (fr)
MX (1) MX9203760A (fr)
NL (1) NL8920901A (fr)
SE (1) SE9001308L (fr)
WO (1) WO1990001321A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
JPH0753384A (ja) * 1993-07-13 1995-02-28 Wisconsin Alumni Res Found ２４−エピ−１α−ヒドロキシビタミンＤ２ を含んでなる骨粗鬆症治療剤
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
IL115241A (en) * 1994-09-26 2000-08-31 American Cyanamid Co Calcium dietary supplement
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6096876A (en) * 1997-08-06 2000-08-01 Shriners Hospitals For Children 1-α-hydroxylase materials and methods
EP1719513A4 (fr) * 2004-02-18 2009-05-13 Mercian Corp Procede consistant a prevenir, medicamenter et/ou traiter l'hypocalcemie chez un mammifere domestique
KR101495578B1 (ko) * 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
WO1984004527A1 (fr) * 1983-05-09 1984-11-22 Wisconsin Alumni Res Found PROCEDE DE PREPARATION DE LA VITAMINE D21alpha,25-DIHYDROXYLEE ET DES COMPOSES APPARENTES
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
EP0197514A1 (fr) * 1985-04-04 1986-10-15 The General Hospital Corporation Composition pharmaceutique utilisée pour augmenter la masse osseuse

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
WO1984004527A1 (fr) * 1983-05-09 1984-11-22 Wisconsin Alumni Res Found PROCEDE DE PREPARATION DE LA VITAMINE D21alpha,25-DIHYDROXYLEE ET DES COMPOSES APPARENTES
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
EP0197514A1 (fr) * 1985-04-04 1986-10-15 The General Hospital Corporation Composition pharmaceutique utilisée pour augmenter la masse osseuse

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Acta Endocrinol. (Copenh.), Volume 16, No. 4, August 1984, G.O.J. SJODEN et al.: "Effects of 1alfaOHD2 on Bone Tissue. Studies of 1alfa OHD2 and 1alfaOHD3 in Normal Rats and in Rats Treated with Prednisolone", pages 564-568 *
Arch. Biochem. Biophys., Volume 186, No. 1, February 1978, Academic Press, Inc., L.E. REEVE et al.: "Biological Activity of 1 alfa-Hydroxyvitamin D2 in the Rat", pages 164-167 *
J. Nutre., Volume 114, 1984, American Institute of Nutrition, G. SJODEN et al.: "Antiarchitic Activity of 1alfa-Hydroxyergocalciferol and 1alfa-Hydroxycholecalciferol in Rats", pages 2043-2046 *
Proc. Soc. Exp. Biol. Med., Volume 178, 1985, Society for Experimental Biology and Medicine, G. SJODEN et al.: "1alfa-Hydroxyvitamin D2 is Less Toxic than 1alfa-Hydroxyvitamin D3 in the Rat (42028)", pages 432-436 *
Science, Volume 186, No. 4168, 1974, H.Y.P. LAM: "1alfa-Hydroxyvitamin D2: a Potent Synthetic Analog of Vitamin D2", pages 1038-1040 *

Also Published As

Publication number Publication date
EP0381750A1 (fr) 1990-08-16
CA1341408C (fr) 2002-12-10
DE68919673T2 (de) 1995-06-01
AU634490B2 (en) 1993-02-25
GB2231794A (en) 1990-11-28
MX9203760A (es) 1992-09-01
EP0381750B1 (fr) 1994-11-30
WO1990001321A2 (fr) 1990-02-22
GB2231794B (en) 1992-01-15
JPH03501388A (ja) 1991-03-28
SE9001308D0 (sv) 1990-04-10
DE68919673D1 (de) 1995-01-12
SE9001308L (sv) 1990-04-10
GB9006990D0 (en) 1990-08-29
NL8920901A (nl) 1990-07-02
ATE114471T1 (de) 1994-12-15
AU4220389A (en) 1990-03-05
JP3030854B2 (ja) 2000-04-10

Similar Documents

Publication Publication Date Title
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
HK1004257A1 (en) Use of droloxifene in the treatment of bone diseases
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
HUT72670A (en) Containing galanthamine pharmaceutical composition for treating nicotine dependence
GB2235626B (en) Inhalation medicaments for treating respiratory disorders
EP0401903A3 (fr) Utilisation de vanilloides dans le traitement des maladies ou des troubles respiratoires
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
SE7612534L (sv) Forfarande for framstellning av farmaceutiska preparat for behandling av storningar i kalciumemnesomsettning
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
WO1990001321A3 (fr) Procede de traitement et de prevention de la perte de masse osseuse
HK1029738A1 (en) A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor.
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
EP0304986A3 (en) Methods for the treatment of osteoporosis and related disorders
GR3034338T3 (en) Therapeutic system for treating psoriasis
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
CA2385755A1 (fr) Prevention du cancer colorectal
EG17992A (en) Preparation of a medicament for arthritis and theumatism
TW253837B (fr)
CA2131822A1 (fr) Utilisation de l'oestriol pour traiter l'osteoporose climaterique
KR980700083A (ko) 골다공증 치료 주기용 키트(KIT for Osteoporosis Treatment Cycle)
JPS56103114A (en) Drug for osteoporosis comprising 24r- hydroxycholecalciferol
DE69528068D1 (de) Conagenine zur prävention und behandlung von diarrhöe
FR2432869A1 (fr) Compositions pour le traitement de l'osteoporose associant la calcitonine et le phosphore
WO2004078145B1 (fr) Therapie combinatoire utilisant un acetate de glatiramere et la simvastatine dans le traitement de la sclerose en plaques
Feuerstein et al. Single drug therapy with sodium valproate in primary generalized epilepsy. Phase 2: Long term efficacy and tolerance study.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1989910341

Country of ref document: EP

AK Designated states

Kind code of ref document: A2

Designated state(s): AU DE GB JP NL SE

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 90013087

Country of ref document: SE

WWP Wipo information: published in national office

Ref document number: 90013087

Country of ref document: SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU DE GB JP NL SE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE FR GB IT LU NL SE

RET De translation (de og part 6b)

Ref document number: 3990902

Country of ref document: DE

Date of ref document: 19900719

WWE Wipo information: entry into national phase

Ref document number: 3990902

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 1989910341

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1989910341

Country of ref document: EP